Onconetix (NASDAQ:ONCO) Issues Earnings Results, Beats Expectations By $44,973.99 EPS

Onconetix (NASDAQ:ONCO – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($76.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($45,050.00) by $44,973.99, FiscalAI reports. Onconetix had a negative return on equity of 91.95% and a negative net margin of 1,575.89%. The business had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.10 million.

Onconetix Stock Up 3.1%

Onconetix stock opened at $3.00 on Wednesday. Onconetix has a 12 month low of $2.76 and a 12 month high of $1,610.00. The stock’s 50 day moving average is $5.99 and its 200-day moving average is $102.80.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Weiss Ratings downgraded shares of Onconetix from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday. Wall Street Zen upgraded shares of Onconetix from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock presently has an average rating of “Sell”.

View Our Latest Stock Report on ONCO

Onconetix Company Profile

(Get Free Report)

Onconetix, Inc. is a biotechnology company focused on cancer-related diagnostics and therapeutics, with an emphasis on prostate health. Its portfolio includes Proclarix, a blood-based diagnostic test developed to help assess prostate cancer risk. Proclarix was developed by Swiss company Proteomedix, which Onconetix acquired in 2023. The test has received a CE mark for use in Europe; its availability and regulatory status may differ in other markets. Onconetix was formerly known as Blue Water Biotech before adopting its current name in 2024.

Read More

Earnings History for Onconetix (NASDAQ:ONCO)

Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.